Presenting author Leisha Emens outlines exploratory efficacy analysis results from IMpassion130 showing that programmed cell death ligand 1 in immune cells is a robust predictive biomarker for selecting women with metastatic triple-negative breast cancer who may benefit from first-line atezolizumab plus nab-paclitaxel treatment (6:19).
Francois-Clement Bidard reports findings that circulating tumour cell count could help oncologists choose between first line hormone therapy and chemotherapy in women with oestrogen receptor positive, HER2-negative metastatic breast cancer (3:23).
Aditya Bardia explains the importance of research done by him and his colleagues validating pCR as a robust surrogate biomarker for outcomes particularly in women with triple negative and HER2-positive breast cancer (5:26).
Ann Partridge discusses the E5103 study findings regarding the quality of life issues faced by women undergoing mastectomy and the need to continue monitoring them long term (5:14).
Presenting author Zaida Morante discusses findings showing that the greater the delay in initiating adjuvant chemotherapy the worse a woman’s outcome in terms of overall and disease-free survival (2:59).
Andrea DeCensi outlines his study findings demonstrating that low-dose tamoxifen 5 mg/day significantly lowers the recurrence of intraepithelial neoplasia versus placebo without increasing endometrial cancer and deep vein thrombosis (3:32).
Emiel Rutgers gives an overview of the 10-year follow-up results from the EORTC AMAROS trial demonstrating that radiotherapy has equivalent locoregional control to that of axillary lymph node dissection but with a reduced risk of lymphedema (4:28).
Charles Geyer reports his phase III study findings showing the potential for adjuvant trastuzumab emtansine as a new standard of care in women with HER-2 positive, early breast cancer and residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy (7:56).
Frank Vicini discusses his research showing that while partial breast irradiation after lumpectomy is not equivalent to whole breast irradiation for long-term control of ipsilateral breast tumour recurrence, the difference is small (2:27).
Jorge Cortes outlines the findings from the Quantum-R trial of quizartinib in patients with relapsed/refractory acute myeloid leukaemia with a FLT3-internal tandem duplication and a poor prognosis (5:58).
Frederick Locke discusses long-term follow-up results from the ZUMA-1 trial, demonstrating high rates of durable response to axicabtagene ciloleucel treatment among patients with refractory large B-cell lymphoma (4:28).
Study author Alok Khorana discusses the results of the CASSINI trial, demonstrating a reduction in venous thromboembolism during treatment with rivaroxaban among patients with cancer (2:54).
Piers Blombery comments on his study results demonstrating that the BCL2 Gly101Val mutation impairs binding of venetoclax to BCL2, leading to an increased risk of chronic lymphocytic leukaemia progression during treatment (2:56).
Richard Maziarz takes us through the long-term follow-up results of the JULIET trial indicating that the CAR T-cell therapy tisagenlecleucel has achieved a high response rate and enduring responses in adults with relapsed or refractory diffuse large B-cell lymphoma (6:38).
Viola Poeschel outlines findings from the FLYER trial, showing that a six-cycle R-CHOP plus rituximab regimen can be reduced to four cycles of R-CHOP plus rituximab without compromising efficacy in younger patients with diffuse large B-cell lymphoma and a favourable prognosis (4:33).
Presenting author Fausto Castagnetti discusses the results of their study assessing the best score to predict outcomes in older patients with chronic myeloid leukaemia (4:17).
Barbara Burtness talks through the results of the KEYNOTE-048 trial comparing pembrolizumab alone or with chemotherapy versus the EXTREME regimen for patients with recurrent or metastatic head and neck cancer (5:10).
Massimo Cristofanilli discusses the latest results from the PALOMA-3 trial investigating the addition of the CDK4/6 inhibitor palbociclib to fulvestrant in previously treated advanced breast cancer (5:21).
Hisham Mehanna describes the results of the De-ESCALaTE HPV trial comparing cetuximab versus cisplatin for the treatment of low-risk oropharyngeal cancer patients undergoing radiotherapy (5:43).
Peter Schmid discusses the progression-free and interim overall survival results for atezolizumab plus nab-paclitaxel in the setting of metastatic triple-negative breast cancer (5:24).
Apostolia Tsimberidou discusses the findings of the IMPACT study, looking at the survival benefits of matching targeted treatments to the genetic alterations of tumors across multiple cancer types (7:56).
Arnaud Méjean presents the CARMENA trial findings, suggesting that cytoreductive nephrectomy may no longer be the standard of care for metastatic renal cell carcinoma in the era of sunitinib (4:21).
Joseph Sparano gives an overview of his team's findings regarding a 21-gene prognostic test that could help tailor treatment for women with early breast cancer (3:24).
Lead author Daniel George discusses his findings of a greater and longer lasting treatment effect with abiraterone acetate and prednisone in Black than White men with metastatic castration-resistance prostate cancer (3:59).